ARKG is trading at $54.48, down 4.03%, with no specific catalyst identified for the decline. - U.S. stocks are broadly higher as oil prices and Treasury yields ease; trade data and Fed speakers remain in focus. - Genmab and AbbVie reported positive Phase 3 lymphoma results, and European healthcare advanced. - Available evidence does not identify a specific ARKG holding or sector-wide catalyst; the drop appears fund-specific or driven by unreported constituents.